OBJECTIVE: To elucidate the growth and development of @entity1 with @entity699 ( @entity699 ) in adolescence. METHODS: We analyzed the clinical data of 19 @entity1 aged under 18 with @entity699 . We divided the @entity1 into two groups according to the height at diagnosis. The @entity1 under the 3rd percentile were in the @entity851 group (n=12), and the others in the non- @entity851 group (n=7). The intergroup differences in disease course, age of onset, and 24-hour urinary free @entity701 were analyzed. RESULTS: The median age at diagnosis was 13 years. The median disease course was 0.9 years. All those @entity1 presented with typical clinical characteristics of @entity699 . Twelve cases (63.2%) were in @entity851 group. The disease course of the @entity851 group was found significantly longer than that of the non- @entity851 group [(2.7   1.7) years vs. (0.8   0.6) years, P=0.013], but no significant difference was found in the age of onset (P=0.530) or 24-hour urinary free @entity701 (P=0.919) between the two groups. CONCLUSIONS: The data suggest that @entity851 is common in adolescent @entity699 @entity1 . The growth delay may be correlated to the disease course of @entity699 .

Growth and development of adolescent @entity1 with XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity851 :: ('MESH:D006130', 'Disease') :: ['short stature'] @entity701 :: ('MESH:D006854', 'Chemical') :: ['cortisol'] @entity699 :: ('MESH:D003480', 'Disease') :: ['CS', "Cushing's syndrome"]
@entity699 :: (MESH:D003480,Disease) :: ['Cushing's syndrome']
